Compugen Ltd. (CGEN)
-NasdaqCM 5.58 
0.04(0.72%) May 17, 3:59PM EDT
| Prev Close: | 5.54 |
|---|
| Open: | 5.57 |
|---|
| Bid: | 4.40 x 100 |
|---|
| Ask: | 7.13 x 1500 |
|---|
| 1y Target Est: | 6.60 |
|---|
| Beta: | 1.97 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 5.50 - 5.63 |
|---|
| 52wk Range: | 2.96 - 6.32 |
|---|
| Volume: | 27,474 |
|---|
| Avg Vol (3m): | 152,317 |
|---|
| Market Cap: | 208.04M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.36 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Compugen's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Apr 25)
- Compugen Ltd. Reports First Quarter 2013 Financial ResultsBusiness Wire(Thu, Apr 25)
- Compugen to Present at the 12th Annual Needham Healthcare ConferenceBusiness Wire(Tue, Apr 23)
- Compugen First Quarter 2013 Conference Call Scheduled for Thursday, April 25, 2013 at 10:00 AM EDTBusiness Wire(Thu, Apr 18)
- Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer TherapyBusiness Wire(Wed, Apr 17)
- Biotechs That Tackle Toxicity: Huge Global Market AwaitsMinyanville(Tue, Apr 9)
- Biotechs That Tackle Toxicity: Huge Global Market Awaitsat Minyanville(Tue, Apr 9)
- Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer TherapyBusiness Wire(Tue, Apr 2)
- COMPUGEN LTD FinancialsEDGAR Online Financials(Wed, Mar 27)
- Compugen's CEO Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Feb 20)
- Compugen Ltd. Reports Fourth Quarter and Calendar 2012 Financial ResultsBusiness Wire(Wed, Feb 20)
- CORRECTING and REPLACING Compugen Fourth Quarter 2012 Conference Call Scheduled for Wednesday, February 20, 2013 at 10:00 AM ESTBusiness Wire(Tue, Feb 12)
- Compugen to Present at the Molecular Medicine Tri-Conference 2013 in San FranciscoBusiness Wire(Tue, Feb 5)
- Compugen Presents at American Association of Cancer Research Special Conference on Tumor ImmunologyBusiness Wire(Tue, Dec 4)
- Show Me The Money: ADC Revenue Payloads Miss The Markat Seeking Alpha(Mon, Nov 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 511.26 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel.
View More